MONO-LINYAH Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mono-linyah, and when can generic versions of Mono-linyah launch?
Mono-linyah is a drug marketed by Novast Labs Ltd and is included in one NDA.
The generic ingredient in MONO-LINYAH is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
Summary for MONO-LINYAH
Anatomical Therapeutic Chemical (ATC) Classes for MONO-LINYAH
US Patents and Regulatory Information for MONO-LINYAH
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novast Labs Ltd | MONO-LINYAH | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 090523-001 | May 23, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |